Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients
- 155 Downloads
The nonlinear disposition kinetics of 5-fluorouracil (5-FU) were investigated in 6 patients with colorectal carcinoma. Each patient randomly received two single, intravenous doses of 5-FU (7.5 and 15 mg/kg) on separate days. Venous blood and urine samples were collected just prior to and for 5 h after drug administration. In addition to the kinetic studies, the in vitro whole blood/plasma concentration ratio and stability of 5-FU at 37°C were determined in whole blood from normal volunteers and from 5 patients with colorectal carcinoma.
A disproportionate increase in area under the curve and corresponding decrease in total body clearance with increasing dose was observed suggesting dose-dependent behavior of 5-FU. Doubling the dose was accompanied by a 36% decrease in nonrenal clearance but no apparent change in renal clearance. Therefore, the mechanism for dose-dependent elimination appears to be primarily associated with nonrenal processes. The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12.3 versus 6.2 min). The log-linear decline in plasma concentrations and increase in half-life with dose suggest the potential role of product-inhibition as an explanation for the observed nonlinearity in 5-FU elimination.
The present study demonstrates that 5-FU degrades when incubated in whole blood. This most likely reflects metabolism in red blood cells or other blood-formed elements since 5-FU was stable in plasma. Although degradation in whole blood occurs, the estimated whole blood clearance does not contribute significantly to the observed total body clearance value. These findings suggest the possibility of pulmonary clearance of 5-FU.
Key words5-fluorouracil colorectal carcinoma pharmacokinetics product-inhibition blood clearance
Unable to display preview. Download preview PDF.
- 1.Myers C (1981) The pharmacology of the fluropyrimidines. Pharmacol Rev 33: 1–15Google Scholar
- 2.Gustavsson B, Hafstrom L (1981) Adjuvant and pallative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review. Acta Chir Scand [Suppl] 504: 1–28Google Scholar
- 3.Collins J, Dedrick R, King F, Speyer J, Myers C (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin Pharmacol Ther 28: 235–246Google Scholar
- 4.Spector W (1956) Handbook of biological data. Saunders, Philadelphia, p 279Google Scholar
- 5.Schaaf L, Ferry D, Hung C, Perrier D, Edwards IR (1985) Analysis of 5′-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography. J Chromatogr 342: 303–313Google Scholar
- 6.Benet L, Galeazzi R (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074Google Scholar
- 7.Perrier D, Mayersohn M (1982) Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71: 372–373Google Scholar
- 8.Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558Google Scholar
- 9.Lam F, Longnecker M (1983) A modified Wilcoxon rank sum test for paired data. Biometrika 70: 510–513Google Scholar
- 10.Bradley S, Ingelfinger F, Bradley G (1952) Hepatic circulation in cirrhosis of the liver. Circulation 5: 419–429Google Scholar
- 11.Finch R, Bending M, Lant A (1979) Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 7: 613–617Google Scholar
- 12.Cadman E, Heimer R, Davis L (1979) Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 205: 1135–1137Google Scholar
- 13.Garrett E, Hurst G, Green J Jr (1977) Kinetics and mechanisms of drug action on microorganisms XXIII: Microbial kinetic assay for fluorouracil in biological fluids and it's application to human pharmacokinetics. J Pharm Sci 66: 1422–1429Google Scholar
- 14.Wagner J, Gyves J, Stetson P, Walker-Andrews S, Wollner I, Cochran M, Ensminger W (1986) Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46: 1499–1506Google Scholar
- 15.Gibaldi M, Perrier D (1982) Nonlinear pharmacokinetics. In: Swarbrick J (ed) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
- 16.Perrier D, Ashley J, Levy G (1973) Effect of product inhibition on kinetics of drug elimination. J Pharmacokinet Biopharm 1: 231–242Google Scholar
- 17.Mukherjee K, Heidelberger C (1960) Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 235: 433–437Google Scholar
- 18.Aubert C, Cano J, Rigault J, Seitz J, Carcassonne Y (1981) Pharmacokinetics of 5-fluorouracil: Impact of the measurement of the 5,6-dihydrofluorouracil. Bull Cancer 68: 343–345Google Scholar
- 19.Aubert C, Sommadossi J, Coasslo P, Cano J, Rigault J (1982) Quantitative analysis of 5-fluorouracil and 5,6-dihydrofluorouracil in plasma by gas chromatography mass spectrometry. Biomed Mass Spectrom 9: 336–339Google Scholar
- 20.Benet L, Massoud N (1984) Pharmacokinetics. In: Benet L, Massoud N, Gambertoglio J (eds) Pharmacokinetic basis for drug treatment. Raven Press, New YorkGoogle Scholar
- 21.Jusko W, Gibaldi M (1972) Effects of change in elimination on various parameters of the two-compartment open model. J Pharm Sci 61: 1270–1273Google Scholar
- 22.Celio L, DiGregorio G, Ruch E, Pace J, Piraino A (1983) Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol 24: 261–266Google Scholar
- 23.Diem K, Lentner C (eds) (1970) In: Documenta Geigy, 7th edn. Ciba-Geigy, Basle, SwitzerlandGoogle Scholar
- 24.Lam F, Hung C, Perrier D (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 74: 229–231Google Scholar